Emcure Pharma IPO Subscription Status

Last updated on July 5, 2024

Emcure Pharma IPO subscription started on 3 July 2024 and will close on 5 July 2024. Emcure Pharmaceuticals plans to raise around INR 1,952.03 crores via the IPO. The price band is fixed at INR 960 – 1,008 per share. The Emcure Pharma IPO market lot has 14 shares and the minimum application amount is INR 14,112. The retail quota is 35%, QIB is 50% and NII is 15%.

Check Emcure Pharma IPO subscription status here. The subscription figures are taken from BSE and NSE and are updated at regular intervals. The public issue has QIB, NII, and Retail categories for the subscription. In addition, there are shares reserved for employees and the company is giving nearly 9% discount to its employees. Here you can find Emcure Pharma IPO subscription status segregated by days and investor categories.

Emcure Pharma IPO Subscription Status – Live Updates

Shares allotted to anchor investors are not included in these calculations. Similarly, shares allotted to market makers, if any, are not part of these calculations.

Emcure Pharma – Business Background

Emcure Pharmaceuticals stands as a prominent Indian pharmaceutical entity, dedicated to the advancement, production, and global promotion of an extensive array of pharmaceutical products spanning various critical therapeutic domains. As a research and development (R&D) oriented enterprise, Emcure boasts a distinct product portfolio encompassing oral medications, injectables, and biotherapeutics. This diverse range has facilitated its market penetration into over 70 countries, establishing a robust presence in India, Europe, and Canada.

Emcure Pharmaceuticals has 13 manufacturing facilities across India. The company has witnessed substantial sales expansion in India over the recent years. Its sales in India accounted for 48.28% of the total revenue from operations during FY 2024.

Investor Categories in Emcure Pharma IPO Subscription

The three most important categories of IPO investors defined by SEBI are part of the Emcure Pharmaceuticals IPO.

Qualified Institutional Buyers (QIB) – Examples of QIBs are Foreign Portfolio Investors (FPIs), Scheduled Commercial Banks, Mutual Funds, Venture Capital Funds, Foreign Venture Capital Investors (FVCIs), Alternative Investment Funds (AIFs), Insurance Companies, Provident Funds and Pension Funds with a minimum corpus of INR 250 million.

Generally, 50% of the offer is reserved for QIBs. Some of these are classified as anchor investors which work towards stabilizing an IPO.

Non-Institutional Investor (NII) – These are affluent investors who can invest more than INR 200,000. In other words, these are High Networth Individuals (HNIs). Generally, 15% of the offer is reserved for this category. Bids in the category need to exceed INR 200,000. Typical examples include Category III FPIs, resident Indian individuals, HUFs (in the name of Karta), companies, corporate bodies, eligible NRIs, scientific institutions, societies, and trusts.

The NII category is further divided into two – big and small – the threshold application amount being INR 10,00,000 (INR 10 lakh).

Retail Individual Investor (RII) – This category is purely meant for small investors, whose bid must not exceed INR 200,000 per person. Usually, 35% of total shares are reserved for this category in the case of a company with profitable operations. In the event of the IPO-bound company not fulfilling this criterion, only 10% of shares are reserved for retail investors. 

Employee – Shares reserved for company employees are not part of the Net Offer and there may additionally be a discount on offer price to encourage employees to subscribe. Investors in the employee category may also apply under the retail category in an IPO. Therefore, this category of IPO investors has a unique advantage.

Read Also: Allied Blenders IPO Allotment Status

Emcure Pharma IPO Subscription Status FAQs